Drug Profile
Ioforminol
Alternative Names: AN 113111; GE 145Latest Information Update: 24 Feb 2016
Price :
$50
*
At a glance
- Originator GE Healthcare
- Developer Daiichi Sankyo Company; GE Healthcare
- Class Amides; Aza compounds; Contrast media; Diagnostic agents; Imaging agents; Iodobenzenes; Small molecules
- Mechanism of Action Tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Vascular disorders
Most Recent Events
- 01 Dec 2012 GE Healthcare completes a phase II trial in Vascular disorders (diagnosis, in the elderly) in USA (NCT01252810)
- 01 Aug 2012 GE Healthcare completes a phase I/II trial in Vascular disorders (healthy volunteers) in USA (NCT01672996)
- 07 Jul 2012 GE Healthcare initiates enrolment in a phase I/II trial in Diagnostic imaging (in healthy volunteers) in USA (NCT01672996)